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Abstract The proximal promoter of the telomerase RNA gene,
hTR, contains four Sp1 sites and one CCAAT box. We have
carried out a functional analysis of the role of these sequence
elements. Two Sp1 sites downstream of the CCAAT box medi-
ated negative regulation, while the other two Sp1 sites were
positive regulators with the strongest e¡ect mediated by the
negative regulatory Sp1 site closely £anking the CCAAT box.
Basal transcriptional activity is maintained via the CCAAT box
even when all four Sp1 sites are mutated, suggesting nuclear
factor-Y (NF-Y) is a fundamental regulator of hTR promoter
function. Chromatin immunoprecipitation revealed binding of
NF-Y, Sp1 and TFIIB to the promoter in vivo. Thus the inter-
action of NF-Y at the CCAAT box is pivotal to hTR gene
transcription and surrounding sequence elements may provide
an environment for the regulation of activity through recruit-
ment of additional protein complexes.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The human telomerase core enzyme consists of an essential
RNA molecule, hTR, with a template domain for telomeric
DNA synthesis and of a catalytic protein, hTERT, with re-
verse transcriptase activity. Telomerase activity is undetect-
able in many normal somatic cell types but is re-activated in
the majority of cancer cell lines and human tumours where it
counteracts cell division-associated telomere attrition. Cell
strains with undetectable telomerase activity often spontane-
ously senesce in vitro and experimental inhibition of activity
in cancer cell lines leads to telomere shortening and apoptosis.
Therefore, understanding the mechanisms governing expres-
sion of telomerase activity is of substantial interest. Cellular
control of telomerase expression is complex and reconstitution
of telomerase activity was shown to require expression of both
hTR and hTERT in vitro [1,2]. Transcriptional regulation is
the primary step in eukaryotic gene expression, and appears to
constitute the major mechanism for di¡erential telomerase
gene regulation. It has been reported that up-regulating
hTERT transcription can induce telomerase activity de novo
and extend the lifespan of several normal human cell strains
[3]. Moreover, activation of endogenous hTERT in some
transformed cell lines occurs with concomitant elevation of
hTR transcriptional activity that may suggest partially over-
lapping regulatory mechanisms [4]. In our laboratory we have
previously isolated and characterised the human telomerase
RNA gene promoter and studies of hTR promoter regulation
demonstrated that multiple factors modulate hTR gene ex-
pression [5,6]. However, the functional contribution to tran-
scription of individual sequence elements in the core hTR
promoter has not been determined yet.
Nuclear factor-Y (NF-Y) plays a central role in hTR tran-
scription [6]. NF-Y is a heterotrimeric transcriptional activa-
tor composed of three subunits (NF-YA, B, and C), which
complexes with CCAAT box sequences [7,8]. NF-Y subunit
sequences are highly conserved among eukaryotes and both
NF-YB and NF-YC contain conserved putative histone fold
motifs (HFM) [9,10], showing most similarity to histones H2B
and H2A. Thus NF-Y subunits are capable of participating in
formation of the histone octamer [11]. Studies from several
laboratories have suggested that NF-Y functionally and
physically interacts with other transcription factors or nuclear
proteins both in vitro and in vivo [12,13]. NF-YB and NF-YC
have been demonstrated to interact with TATA binding pro-
tein (TBP) in vitro [14] and NF-Y may therefore serve a
structural role by recruiting TBP and/or TAFIIs to connect
upstream activators with the general polymerase II transcrip-
tion machinery [15,16]. The interaction between NF-Y and
GCN5 results in the modulation of NF-Y transactivation po-
tential by aiding the disruption of local chromatin structure
[17]. A recent study by Park et al. described induction of
TGF-L type II receptor gene transcription involving recruit-
ment of the P/CAF protein to the NF-Y^CCAAT complex
after HDAC inhibitor treatment [18]. Chromatin structure
plays a vital role in transcriptional regulation by restricting
the access of transcription-associated proteins to promoters
and it is likely that the interaction of NF-Y with histones
and with other co-regulators of transcription performs a crit-
ical and central function in the organisation of core promoter
activation.
The core promoter regions of genes orchestrate diverse
functions including polymerase recruitment, promoter activ-
ity, and response to regulatory input [19,20]. The aim of the
present study was to de¢ne the functional cis-acting DNA
elements responsible for basal activity of the hTR core pro-
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moter in human cancer cells and thereby provide a basic
model to aid future studies of hTR promoter regulation. Dis-
ruption of the hTR CCAAT box is known to abrogate basal
activity [6]. In the current study we have analysed the sequen-
ces contributing to basal activity of the hTR promoter in the
hTR- and telomerase-positive 5637 bladder carcinoma cell line
that has previously been included in a comprehensive study of
hTR expression in normal, cancer and telomerase-negative
immortal cell lines [21]. We identi¢ed a strong repressive ac-
tivity acting through a low a⁄nity Sp1 site closely £anking the
CCAAT box. Promoter activity was maintained through the
wild-type CCAAT box after mutation of all four surrounding
Sp1 sites, suggesting that the active core promoter is organised
by NF-Y. This is further supported by the observation that
cotransfection of the three subunits of NF-Y signi¢cantly en-
hanced the activity of reporters lacking all four functional Sp1
sites. Finally, we observed recruitment of NF-Y, Sp1 and
TFIIB to the hTR promoter in vivo using chromatin immu-
noprecipitation (ChIP). Previous structural observations from
the hTR gene have suggested that, in contrast to lower eu-
karyotes which utilise Pol III for transcription of the telomer-
ase RNA gene [22], hTR is likely to be transcribed by Pol II.
This study provides the ¢rst direct evidence that a component
of the Pol II transcriptional machinery is speci¢cally recruited
to the hTR promoter in vivo and provides the ¢rst evidence of
a basal transcriptional unit in the hTR promoter through
which hTR transcription in cancer cells is likely to be organ-
ised predominantly through the activity of NF-Y.
2. Materials and methods
2.1. Materials and cell culture
Antibodies to Sp1 and Sp3 were purchased from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA, USA). Rabbit polyclonal antibody
directed against NF-YA, B and C was obtained from R. Mantovani
(University of Milan, Milan, Italy). The 5637 cell line, originally es-
tablished from the primary bladder carcinoma of a 68 years old man
in 1974, purchased from DSMZ (No: ACC 35). 5637 cells were main-
tained at 37‡C in 5% CO2 in 1640 medium supplemented with 10%
foetal bovine serum, penicillin, and streptomycin.
2.2. Construction of reporter plasmids and mutagenesis
Primers carrying restriction sites were used for polymerase chain
reaction (PCR) with hProm867 [5] as the template to generate a series
of 5P and 3P terminal deletions with compatible ends for cloning as
XhoI/HindIII fragments into the multiple cloning region of the pro-
moter-less luciferase vector pGL3-basic (Promega, Madison, WI,
USA). A two-step cloning strategy was used for site-directed muta-
genesis to prevent unexpected mutations in luciferase reporter vectors:
(i) An hTR 176 bp fragment (2923wt, spanning from 3107 to +69 bp)
was cloned into the XhoI/HindIII sites in pCR-Script1 plasmid vector
(Stratagene, La Jolla, CA, USA), which was used as template for
PCR using a QuikChange1 site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA) following the manufacturer’s instructions. (ii) All
mutation fragments were reconstructed into the XhoI/HindIII sites of
pGL3-basic vectors and veri¢ed by DNA sequencing.
Primers carrying the mutations (Table 1) and a second set of prim-
ers for subcloning were designed. The PCR reaction was performed
with these primers and 2923wt or 2925wt as template to create single
site mutation constructs shown in Fig. 2B. The double site mutation
construct, mSp1(2), or multiple sites mutation constructs, mSp1(3)
and mSp1(4), were generated in several separate PCR reactions using
mSp1.1, mSp1(2), and mSp1(3) constructs as templates.
The following oligonucleotides were used as PCR primers:
hTR23(+69 to +46) HindIII, 5P-cgcaagcttTACGCCCTTCTCAGT-
TAGGGTTAG-3P ; hTR25(+10 to 312) HindIII, 5P-cgcaagctTCCG-
CAACCCGGTGCGCTGCCG-3P ; hTR29(3107 to 388) XhoI, 5P-gc-
gctcgAGCCCGCCCGAGAGAGTGAC-3P ; mCCAAT(374 to 345),
5P-GCGAGAGTCAGCTTGGagtcTCCGTGCGG-3P ; conSp1(349
to 320), 5P-GCGGTCGGCccCCGCcCCCTTTATAAGCCG-3P ;
mSp1.4(+15 to +36), 5P-GGGCCTGGGtaaGGTaaTGGCC-3P.
Nucleotides corresponding to promoter sequences are given in
uppercase letters from 5P end to 3P end. Lowercase letters indicate
mutated nucleotides or clamps for introduction of underlined restric-
tion enzyme sites.
2.3. Transfection and dual luciferase reporter assay
3.0 Wg of hTR promoter plasmids containing ¢re£y luciferase re-
porters were cotransfected into tumour cells with an internal Renilla
luciferase control, pRL-SV40 (Promega) using Superfect transfection
reagent (Qiagen) as previously described [5,6]. For cotransfection,
5637 cells were cotransfected with 0.5 Wg of expression vectors encod-
ing wild-type NF-YA, B and C (kindly donated by Dr R. Mantovani),
1^3 Wg of the plasmids containing the luciferase reporter gene and 0.5
Wg of pRL-SV40 plasmid for control of transfection e⁄ciency. The
total amount of DNA was kept constant at 10 Wg with salmon sperm
DNA. The activity of both ¢re£y and Renilla luciferase was deter-
mined 48 h later using the dual luciferase assay kit (Promega). A
minimum of three independent transfections were performed in dupli-
cate and speci¢c hTR promoter activity was normalised to protein as
described elsewhere [5,6].
2.4. Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts from cultured 5637 cells were made according to
our previous study [6]. EMSAs were performed using the EMSA kit
(Promega, E3300). 5.0 Wg of nuclear extract proteins were incubated
in 15 ul of reaction containing 4% glycerol, 1 mM MgCl2, 0.5 mM
dithiothreitol (DTT), 0.5 mM ethylenediamine tetraacetic acid
(EDTA), 50 mM NaCl, 10 mM Tris^HCl, pH 7.5 and 2.0 Wg poly
(dI-dC) with or without 100-fold molar excess of unlabelled DNA
competitors on ice for 15 min, followed by addition of the radiola-
belled probe. For supershift assays, antibodies against Sp1, Sp3, NF-
YA, NF-YB or NF-YC, were added to the reaction mixture 25 min
prior to the addition of the probe. All DNA^protein complexes were
resolved by electrophoresis on 5% native polyacrylamide. The follow-
ing double-stranded oligonucleotides were used in EMSAs as probes
and/or competitors: consensus Sp1, 5P-ATTCGATCGGGGCGGGG-
CGAGC-3P, (Promega, E323A); TFIID, 5P-GCAGAGCATATAAG-
GTGAGGTAGGA-3P (Promega, E322B). The other oligonucleotides
are shown in Table 1.
2.5. ChIP assays
Formaldehyde cross-linking and ChIP were performed as described
previously [23]. In brief, 5637 cell cultures were treated with form-
aldehyde for 10 min followed by the addition of glycine to a ¢nal
concentration of 0.125 M. Cells were then washed twice with cold
phosphate-bu¡ered saline (PBS) and were resuspended in lysis bu¡er
(1% sodium dodecyl sulphate (SDS), 10 mM EDTA, 50 mM Tris^
HCl, pH 8.1) with a proteinase inhibitor. After brief sonication to
yield an average DNA fragment size of 500 bp, the DNA fragments
cross-linked to the proteins were enriched by immunoprecipitation
with speci¢c antibodies. A ‘no antibody’ sample was included as a
negative control for the immunoprecipitation step. After reversal of
the cross-links and DNA puri¢cation, the extent of enrichment was
monitored by PCR ampli¢cation of promoters using forward and
reverse primers to the hTR (5P-TACGCCCTTCTCAGTTAGGGTT-
AG-3P and 5P-AGCCCGCCCGAGAGAGTGAC-3P) and hsp70 (5P-
CCTCCAGTGAATCCCAGAAGACTCT-3P and 5P-TGGGACAA-
CGGGAGTCACTCTC-3P) gene promoter fragments [24] and to the
GAPDH coding region as a negative control (5P-TGAAGGTCGGA-
GTCAACGGATTTGGT-3P and 5P-CATGTGGGCCATGAGGTC-
CACCAC-3P). The PCR product was separated by agarose gel elec-
trophoresis. The input sample (the supernatant of the ‘no antibody’
sample) was processed with the rest of the samples from the point at
which the cross-links were reversed.
3. Results
3.1. Mutation of Sp1 sites inhibits DNA binding complexes
Our previous study [6] showed that Sp1/Sp3 factors activate
and repress hTR promoter activity and four Sp1 sites (termed
Sp1.1, Sp1.2, Sp1.3 and Sp1.4) have been detected in the hTR
proximal promoter from 3107 to +69 bp (Fig. 2A). In that
FEBS 26953 5-2-03
J. Zhao et al./FEBS Letters 536 (2003) 111^119112
study, we used EMSA to examine complex formation in 5637
nuclear extracts using the oligonucleotides h9, h4 and h111,
which correspond to individual Sp1/Sp3 sites within the hTR
proximal promoter (Table 1). Supershift analysis previously
identi¢ed speci¢c Sp1 and Sp3 binding complexes, labelled
in Fig. 1 [6]. To clarify the molecular basis for the response
to Sp1/Sp3 protein binding, we ¢rst introduced speci¢c muta-
tions at each of these sites (for sequences see Table 1). As
shown in Fig. 1, 32P-labelled probes h4, h9 and h111 form
DNA^protein binding complexes (lanes 1, 6 and 10 respec-
tively), formation of which is inhibited by the respective un-
labelled oligonucleotide (lanes 2, 8 and 11). Oligonucleotides
harbouring mutations in Sp1 binding sites did not compete
with the labelled DNA for protein complex formation (lanes
3, 4, 9, 12 and 13). Oligonucleotide h9 contains a potential
TATA box, however mutant mut13 (from TATA to CGAC)
retained the ability to displace nuclear protein binding (lane
5). Additionally, a consensus TFIID oligonucleotide used in
EMSA did not compete for h9 binding (data not shown). To
con¢rm that the sequence change did not introduce a new
protein binding site in mut12 and to assess the possibility of
proteins binding at the TATA box after destruction of the Sp1
site, EMSA was performed using labelled mut12 oligonucleo-
tide as a probe. No speci¢c DNA^protein complex formation
was detected within this oligonucleotide (data not shown).
These results demonstrated that the hTR TATA box (328/
325) is not critical for DNA^protein interaction.
3.2. Re¢ning the functional region in hTR proximal promoter
We previously reported that NF-Y binding at the hTR
CCAAT box plays a central role in the maintenance of tran-
scription from the hTR promoter. To further characterise the
functional signi¢cance of the CCAAT box and surrounding
sequence elements, we performed a series of deletion and mu-
tagenesis experiments on a 176 bp fragment of the hTR prox-
imal promoter (2923wt) (Fig. 3). In initial experiments, dele-
tion of the sequence downstream of the transcriptional start
site containing Sp1 sites 1.3 and 1.4 (construct 2925) (Fig. 3A)
resulted in a minor increase in promoter activity while muta-
tion of site Sp1.1 in addition to the downstream deletion
resulted in a signi¢cant enhancement of activity. Thus sequen-
ces surrounding the CCAAT box may play a role in the mod-
ulation of hTR core promoter activity with upstream elements
contributing to transactivation, while the downstream se-
quence elements have a general repressive role.
To characterise the functional relevance of each Sp1 site in
regulation of the hTR promoter, mutant sequences detailed in
Fig. 2B were constructed into hTR promoter reporters (Fig.
3A and B) by site-directed mutagenesis, plasmid constructs
were transiently transfected into 5637 cells and the promoter
activities were monitored. As shown in Fig. 3A, the single site
mutation analysis indicated that: (i) Mutation of the TATA
box from TATA to CGAC in construct mTATA had no e¡ect
on reporter gene expression, consistent with redundancy of
this site. (ii) Mutations of Sp1 sites led to activation or sup-
Table 1
List of oligonucleotides used in EMSA
Oligonucleotide Sequence (5PC3P)




h4(Sp1.2) 3110 ACCAGCCCGCCCGAGAGAGT 391
mut2 ACCAGCCCGAACGAGAGAGT
h112(Sp1.3) 32 CCGGGTTGCGGAGGGTGGGCCTGGG +23
mut3 CCGGGTTGCGGAAAATGGGCCTGGG
h113(Sp1.4) +17 GCCTGGGAGGGGTGGTGGCC +36
mut4 GCCTGGGTAAGGTGGTGGCC
h111(Sp1.3/4) 32 CCGGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCC +36
Bold bases represent mutations with respect to the wild-type sequences. Regulatory motifs underlined have previously been reported [35,36].
Fig. 1. Disruption of Sp1/Sp3 binding to hTR promoter Sp1 sites. Nuclear extract was mixed with radiolabelled oligonucleotide probes as indi-
cated at the top of each panel and analysed by EMSA. Competition experiments were performed in the presence of 100-fold molar excess of
cold competitors. Speci¢c complexes binding Sp1/Sp3 are indicated on the left by arrows.
FEBS 26953 5-2-03
J. Zhao et al./FEBS Letters 536 (2003) 111^119 113
pression of promoter activity. Mutation of the Sp1.2 or Sp1.3
sites alone resulted in a minor decrease in promoter activity
relative to wild type. Mutation of site Sp1.1, which £anks the
hTR CCAAT box, led to the most signi¢cant e¡ect on pro-
moter activity (an increase of about four-fold), and mutation
of site Sp1.4 also resulted in a small increase in transcriptional
activity of 1.5-fold relative to wild type. These data indicate
that Sp1.2 and Sp1.3 elements are the sites of action for an
activator of hTR promoter activity, and Sp1.1 and Sp1.4 el-
ements are the sites of action for a repressor of hTR promoter
activity with Sp1.1 apparently mediating the most dominant
e¡ects. Mutation of the CCAAT box (construct mCCAAT)
resulted in abrogation of basal activity. Since Sp1.1 £anks the
CCAAT box and mediates a strong negative e¡ect, there are
at least two interpretations of these data: In one scenario,
NF-Y is a vital basal regulator of the hTR promoter whose
e¡ects are critical for maintenance of basal activity. An alter-
native explanation is that the CCAAT box mediates a positive
e¡ect, but it is the strong repressive nature of the intact Sp1.1
site in the single mutant construct that is responsible for re-
pression of activity in the absence of an intact CCAAT box.
To clarify this issue, we performed a cotransfection analysis
using the wild-type 2923 and mCCAAT constructs cotrans-
fected with Sp1 or Sp3 expression constructs. We previously
showed that transient overexpression of Sp1 or Sp3 protein
can, respectively, up- or down-regulate the proximal hTR
promoter activity. We now demonstrate that the stimulatory
e¡ect of Sp1 and the repressive e¡ect of Sp3 cotransfections
are lost in the context of a construct lacking the wild-type
CCAAT box (Fig. 3C), strongly suggesting that the regulatory
roles of the Sp1/Sp3 binding sites in the hTR promoter
are also dependent on the presence of an NF-Y binding ele-
ment.
To further determine how the factors binding to Sp1 ele-
ments interact and coordinate hTR transcription, double and
multiple site-directed mutant constructs were created. As
shown in Fig. 3B, mutations of Sp1.2 and Sp1.1 sites together
in construct mSp1(2) had a similar e¡ect to mutation of Sp1.1
alone. Since deletion analysis indicates that upstream se-
quence contributes to transactivation, it is likely that positive
regulation can be maintained in the absence of activation by
Sp1.2 by factors interacting with Sp1.3. In keeping with this
hypothesis, mutation of three Sp1 sites in construct mSp1(3)
resulted in a large decrease in promoter activity relative to the
double mutant. These data suggest that transactivation un-
masked by ablation of the strong repressive e¡ect of Sp1.1
can be mediated either through Sp1.2 or Sp1.3 with neither
site showing dominance. The activity of construct mSp1(3)
was only slightly greater than the wild type and interestingly,
the activity of a construct with combined mutation of all four
Sp1 sites within the core promoter (construct mSp1(4)) was
similar to the wild-type activity. These data suggest that the
major basal activator of the hTR promoter is NF-Y binding
at the CCAAT box and that the e¡ect of NF-Y mediated
transactivation of the core promoter may be modulated by
the presence of a strong repressive element at Sp1.1.
3.3. A critical Sp1 site in the hTR core promoter represses
NF-Y-organised transactivation
The presence of multiple Sp1 sites exhibiting functional
divergence within the hTR promoter, suggests that hTR tran-
scriptional regulation may involve complex interactions be-
tween Sp1 and Sp3. It has been demonstrated that the repres-
sion of gene promoter activity in general by Sp3 is strictly
dependent on the promoter context of the DNA binding sites
[25]. Sp1.1 localises to a region in the hTR promoter between
the CCAAT box and the transcriptional start site, and is
adjacent to the redundant TATA box and may thus be opti-
Fig. 2. hTR core promoter and mutation constructs (3107/+69). A: Schematic illustration of the hTR gene promoter. Regulatory sequences
(GC box and CCAAT box sites) and their cognate binding factors are shown. The Sp1 and NF-Y binding nucleotide sequences are indicated
below. Core promoter regulatory domains identi¢ed in this study are illustrated. B: The sequence of the wild-type hTR core promoter (3107/
+69) is shown at the top. The name of each mutant construct is indicated on the left hand side. The number on either side of the sequence is
related to the transcriptional start site. Dashes indicate an identical sequence to wild type. Mutated nucleotides are shown below the wild-type
sequence. The hTR template region is indicated in bold.
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Fig. 3. Scanning mutational analysis of the hTR core promoter. A: Promoter activities of deletions and site-replaced mutant constructs: The
various symbols or circles represent the di¡erent transcription factor binding sites indicated at the top. Transcriptional start site indicated as
broken line. The constructs are shown with a black ellipsoid shape indicating a site-replaced mutation in one or more positions and open ellip-
soids representing unmodi¢ed sites. The promoter activity is shown on the right hand side. 3 Wg of each plasmid were used for transient trans-
fection analysis in 5637 cells. Promoter activities of the mutant constructs were assayed by transfection and compared to the wild-type pro-
moter. The pRL-SV40 vector was used as an internal control to normalise the transfection e⁄ciency. For each transfection the mean and
standard deviation of data from three experiments are shown. B: Double and multiple mutation analysis. C: Promoter activity of wild-type
and CCAAT mutant reporters cotransfected with Sp1 or Sp3.
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mally placed to generate a maximal repressive e¡ect. It is
unknown to what extent the a⁄nity of Sp1/Sp3 binding at
the non-consensus Sp1.1 site mediates the repressive e¡ect,
and to what extent those e¡ects are mediated by its proximity
to the CCAAT box. To address this issue, we investigated the
relative a⁄nities of each of the four Sp1 sites for Sp1/Sp3
binding in parallel competition experiments utilising a consen-
sus Sp1 oligonucleotide as the probe and competing cold hTR
Sp1 oligonucleotides in molar excess. As shown in Fig. 4A,
cold oligonucleotides corresponding to sites Sp1.3 and Sp1.4
were able to e⁄ciently compete with binding to labelled con-
sensus Sp1 oligonucleotides, whereas inhibition of complex
formation by Sp1.1 and Sp1.2 was less e⁄cient. The relative
a⁄nities of the four Sp1 sites in the hTR core promoter are
Sp1.4s Sp1.3s Sp1.2s Sp1.1 (Fig. 4B). Therefore, the Sp1.1
site showed the lowest a⁄nity for Sp1/Sp3 binding.
Since mutation of the Sp1.1 site results in the most signi¢-
cant e¡ect on promoter activity and since this site has the
lowest a⁄nity for Sp1/Sp3 binding, it seems likely that rela-
tively weak binding to Sp1.1 can greatly inhibit hTR core
promoter activity, suggesting the likelihood of a positional
importance associated with the site and the possibility of func-
tional interplay with NF-Y. We speculated that increasing the
a⁄nity of the Sp1.1 site for Sp1/Sp3 binding should enhance
the inhibitory e¡ect of this element. To test this model and to
extend the understanding of the role of NF-Y in the regula-
tion of hTR transcription we generated several mutant con-
structs from the proximal promoter (2923wt; 3107/+69).
Consistent with the hypothesis that the positioning of Sp1.1
mediates a signi¢cant repressive e¡ect on hTR even with rel-
atively low a⁄nity binding, replacement of this sequence with
a consensus Sp1 binding site enhanced the repressive e¡ect
unmasked in Sp1.1 mutants (Fig. 5A), while mutation of the
CCAAT box severely retarded the basal activity. These data
Fig. 4. Di¡erential a⁄nities of the hTR core promoter Sp1 sites. A: Consensus Sp1 oligonucleotide was radiolabelled by kinase treatment using
[Q-32P]dATP. Nuclear extract protein was incubated with increasing concentrations of each unlabelled oligonucleotide for 10 min followed by in-
cubation with the Sp1 probe and electrophoresed on a 5% polyacrylamide gel. Quantitative analysis of the dried gel was performed using both
a computing phosphorimager with ImageQuant software (Molecular Dynamics) and autoradiography on Kodak XAR-5 ¢lms. Three major
DNA^protein complexes are indicated with arrows, and lane 1 without competitor was used as a control for quantitative analysis. B: Quanti¢-
cation of the data. Molar excess (from 5U, 10U, 100U, 200U to 500U fold molar present in lanes 2^6 or lanes 7^11) of unlabelled oligonu-
cleotides (h4, h9, h112 and h113) are indicated. Sequences of the oligonucleotide used in competition are shown in Table 1.
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underscore the importance of NF-Y mediated transcriptional
control of hTR and suggest that inhibition by factors inter-
acting with the Sp1.1 site is mediated primarily in cooperation
with NF-Y.
To reassess the importance of the hTR CCAAT box and
address whether NF-Y can directly activate transcription, we
performed a transient cotransfection experiment to reconsti-
tute the three subunits of NF-Y (NF-YA, B and C) in 5637
cells. In this experiment, two promoter contexts were used to
investigate NF-Y transactivation; a core promoter construct,
2923wt and the core promoter with all four Sp1 sites mutated,
2923mSp1(4). As shown in Fig. 5B, transient expression of
NF-YA alone or with NF-YB had no e¡ect on promoter
activities, but co-expression of all three subunits together dra-
matically induced the activity of all promoter constructs, even
those lacking all four Sp1 binding elements (from 2.5- to 4.5-
fold induction). These results demonstrated that NF-Y is a
strong activator and that NF-Y alone can activate hTR trans-
activation without Sp1 binding.
3.4. NF-Y interacts with the hTR promoter in vivo
The complete set of general transcription factors are
thought to form the transcription initiation apparatus at
most promoters, but a direct test of this model in hTR has
not been carried out in vivo. Moreover, while the telomerase
RNA genes of lower eukaryotes are transcribed by Pol III
dependent mechanisms, the structure of the hTR gene and
promoter indicates that it may be regulated by Pol II
[5,6,22], suggesting that the mechanisms regulating telomerase
RNA expression may be evolutionarily divergent. To deter-
mine whether NF-Y, Sp1 and TFIIB, a component of the
general Pol II transcriptional machinery, become associated
with the active hTR promoter, we performed a ChIP assay
in 5637 cells. 5637 cells were treated with formaldehyde to
cross-link proteins to DNA. After sonication, the cross-linked
chromatin was immunoprecipitated using anti-NF-YB, Sp1
and TFIIB antibodies. After immunoprecipitation, enrich-
ment of the endogenous hTR promoter fragment in each sam-
Fig. 5. Functional analysis of hTR gene transcription regulation by
the CCAAT box and Sp1.1. A: Comparison of the activity of core
promoter regions containing the wild-type, mutant or consensus Sp1
sites or mutant CCAAT box. Promoter activities were assayed by
transient transfection and results are expressed as the percent of lu-
ciferase activity normalised by Renilla and compared to the wild-
type promoter. For each transfection the mean and standard devia-
tion of data from three experiments are shown. B: E¡ects of over-
expression of NF-Y on hTR core promoter activity. 5637 cells were
cotransfected with 3.0 Wg of 2923wt (3107/+69) or 2923mSp1(4) lu-
ciferase reporter constructs together with 0.5 Wg of expression vec-
tors encoding wild-type NF-YA, B and C. Total input DNA
amount for transfection was adjusted with salmon sperm DNA to
ensure a constant amount in all transfections. After 48 h of culture,
cells were harvested, and the cell lysate was assayed for Renilla and
luciferase. Data presented are the means of the three independent
experiments performed in duplicate.
Fig. 6. Immunoprecipitation of the hTR promoter from 5637 cells.
Formaldehyde cross-linked chromatin was prepared from 5637 cells
and immunoprecipitated with antibodies to NF-YB (lane 4), TFIIB
(lane 5) and Sp1 (lane 6), or in the absence of antibody (lane 3).
PCR detection of DNA sequences immunoprecipitated with each
antibody is shown in these lanes. Lane 2 shows the supernatant of
the ‘no antibody’ sample. PCR was performed with speci¢c primers
for the hTR promoter or for the Hsp70 promoter and GAPDH
coding region as positive and negative controls. A sample represen-
tative of the total input chromatin (input DNA, lane 1) was in-
cluded in the PCR analysis.
FEBS 26953 5-2-03
J. Zhao et al./FEBS Letters 536 (2003) 111^119 117
ple was monitored by PCR ampli¢cation using primers am-
plifying the hTR promoter region from 3107 to +69 bp. To
con¢rm the speci¢city of the DNA binding activity of factors
at the hTR promoter, PCR ampli¢cations of the Hsp70 pro-
moter which binds Sp1 and the general transcription factor
TFIIB [24], and the GAPDH coding sequence, which has no
binding sites for any of the regulators tested, were included in
parallel experiments as positive and negative controls, respec-
tively (Fig. 6). The results of ChIP experiments performed
with these antibodies indicate that hTR transcription in living
cells involves recruitment of NF-YB, Sp1 and TFIIB factors
to the hTR promoter. This is the ¢rst evidence of a basal
transcriptional mechanism for regulation of the hTR pro-
moter and, taken together, the data presented in this report
give a strong indication that NF-Y is an essential component
involved in the organisation of the hTR basal transcriptional
machinery.
4. Discussion
It is likely that multiple mechanisms regulate the hTR pro-
moter in vivo. We previously observed that NF-Y and Sp1
family transcription factors bound to the hTR promoter to
regulate hTR expression. Additionally, we previously de-
scribed silencing of the hTR promoter in telomerase-negative
immortal cells (ALT cells) by methylation of the CpG island
in which the proximal promoter is located. The silent (meth-
ylated) hTR promoter can be re-activated in some ALT cell
lines by combined treatment with the demethylating agent 5-
AzaC and the histone deacetylase inhibitor TSA [21]. These
studies suggest that regulation of the proximal hTR promoter
may be important for the di¡erential regulation of hTR gene
expression in normal and cancer cells. In this manuscript we
analyse the hTR core promoter and demonstrate the coordi-
nate function of Sp1 and NF-Y binding sequence elements in
the basal activity of the hTR promoter in cancer cells. These
data provide the ¢rst demonstration that the functional hTR
core promoter is composed of four Sp1 sites and a CCAAT
box. In this core promoter: (i) NF-Y binding at the CCAAT
box is crucial for hTR promoter activation. (ii) The TATA
box adjacent to Sp1.1 has no function. (iii) Factors binding to
Sp1 sites nearby the CCAAT box coordinate with NF-Y to
activate or repress hTR transcription. In this model, the tran-
scription factors targeting downstream of the CCAAT box
represent an overall negative e¡ect, although the downstream
region also contains a sequence (Sp1.3) that can act as pos-
itive regulator in the absence of upstream elements that con-
tribute to transactivation. It is possible that di¡erential bind-
ing between normal and cancer cells of factors acting on these
and other promoter elements may partly underlie the cell se-
lectivity of hTR expression. Indeed, we have recently demon-
strated that hTR promoter gene therapy constructs delivered
by adenovirus to a range of human cell lines are di¡erentially
active between normal cells and cancer cells [26]. Therefore,
the present study delineates the fundamental elements of a
core promoter structure that will be helpful for future studies
that may increase our understanding of the di¡erential regu-
lation of hTR expression.
NF-Y^CCAAT complex formation underlies hTR tran-
scriptional regulation and is likely to be in£uenced by sur-
rounding modulators. Single and multiple site-directed muta-
genesis experiments identi¢ed both negative (Sp1.1 and Sp1.4)
and weak positive regulatory elements (Sp1.2 or Sp1.3) (Fig.
3), of which the CCAAT £anking Sp1.1 site appeared to be
the most highly functional. Disruption of Sp1.1 facilitated
transactivation, presumably by factors binding either to the
Sp1.2 or Sp1.3 sites since de-repression of activity was only
observed in constructs with at least one of these sites intact.
These results indicated that hTR transcription can be up- or
down-regulated by surrounding Sp1 sites. However, regula-
tion of the core promoter by Sp1 or Sp3 cotransfection re-
quired an intact CCAAT box and basal promoter activity was
unchanged relative to wild type in a construct lacking all four
Sp1 sites. Interestingly, the latter construct could also be
transactivated by cotransfection of all three NF-Y subunits.
These data indicate that the hTR core promoter can drive
reporter gene expression without Sp1/Sp3 directly binding to
DNA and suggest that the primary basal activator of hTR
transcription is NF-Y while the Sp1/Sp3 binding sites are
more likely to perform regulatory roles.
The sequences controlling basal transcription are common
to many genes and include the TATA box, CCAAT box, Sp1
site and initiator (Inr) sequence elements. Transcription fac-
tors Sp1 and NF-Y have been shown to coordinately regulate
many gene promoters and to physically interact with each
other and with TBP and general transcription factors
[14,16,27]. Moreover, Sp1 sites in TATA-less proximal pro-
moters can regulate start site utilisation [28^30], while the vast
majority of CCAAT boxes have been shown to signi¢cantly
contribute to overall promoter strength and to be strictly re-
quired for gene transcriptional activity [8]. Therefore we sug-
gest that coordination of the factors binding to Sp1 sites and
the CCAAT box constitute the hTR core transcription ma-
chinery in human cancer cells which may mediate the recruit-
ment of components of the Pol II transcriptional apparatus to
the hTR promoter in vivo (Fig. 6). NF-Y binding to the
CCAAT box is a good candidate to organise promoter archi-
tecture and chromatin assembly thereby controlling core hTR
transcription by in£uencing the transcription initiation com-
plex formation. In this speculative model, factors binding to
the region downstream of the CCAAT box in the hTR core
promoter might directly or indirectly in£uence initiator bind-
ing activity leading to transcriptional repression. Other factors
binding to the distal promoter might enhance NF-Ys ability
to recruit general transcription factors in the formation of an
active transcriptional complex.
In the present study, we identi¢ed an NF-Y-organised hTR
core promoter and propose a basal transcriptional mecha-
nism. There are elements in the upstream hTR promoter
that may potentially allow interaction with other co-regula-
tors for modulation of signals between transcription factors
and the core transcriptional machinery. Combinations of
ubiquitous transcription factors with cell type-speci¢c factors
might thereby regulate hTR gene expression in the cell type-
speci¢c manner that has been observed. Studies of the tran-
scriptional regulation of hTR and hTERT promoters will be
essential for the rational development of telomerase-directed
therapeutics [8,21,31^34]. It is possible that a small number of
key transcription factors might be responsible for a complex
set of expression patterns in diverse conditions. Studies of the
functional motif combinations in the hTR promoter may give
more information about molecular mechanisms controlling
di¡erential hTR expression patterns in normal and cancer
cells.
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